pramlintide

The companies are planning late-stage testing of a regimen combining two synthetic hormones called pramlintide and metreleptin.

Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7 AP 2010

Another drug, Amylin Pharmaceuticals Inc. 's combination of pramlintide, also for diabetes, and metreleptin, an analogue of a hormone, reduced body weight on average 12.7% in a phase II study of 177 patients last year.

Drug Makers Seek Antiobesity Blockbuster 2008

Amylin Pharmaceuticals Inc. continues to research that possibility and is in Phase 2 trials of a combination of leptin and pramlintide, a diabetes drug.

Can't Keep the Weight Off? 2008

The U.S. Food and Drug Administration approved Byetta (exenatide) and Symlin (pramlintide acetate) in the spring of 2005, and both injectable drugs are beginning to bring in revenue.

Amylin's Amazing Run Still Has Steam 2006

Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

unknown title 2011

Entered into a research collaboration agreement with the Juvenile Diabetes Research Foundation JDRF to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide with insulin to treat type 1 diabetes

unknown title 2011

SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

Amylin Pharmaceuticals Reports 2010 Financial Results - Yahoo! Finance 2011

Presented a new analysis at the ADA annual meeting that showed SYMLIN® pramlintide acetate injection helped reduce A1C, insulin use and body weight in patients with type 1 diabetes who used insulin pumps

unknown title 2011

While the pramlintide/metreleptin development program has been discontinued, Amylin and Takeda will continue to investigate the previously announced antibody-related laboratory finding with metreleptin treatment in patients who participated in a previously completed clinical study of obesity.

unknown title 2011

The joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase 2 development as a twice-a-day injection formulation.

unknown title 2011